ACC 2019 External Validation Presentation for HART CVE

Validation of a Novel AI-driven multi-biomarker Panel for Accurate Prediction of Incident Cardiovascular Events in Patients with Suspected Myocardial Infarction.

March 17, 2019


  • Predicting future cardiovascular events (CVE) in patients presenting with suspected myocardial infarction (MI) is an unmet clinical need. In a population of patients with suspected MI presenting to the emergency department, we sought to externally validate a multiple biomarker panel for prediction of incident CVE.


  • 748 patients presenting with suspected MI to the emergency department were prospectively recruited. A multiplex assay including 4 biomarkers (NT-proBNP, KIM-1, osteopontin, TIMP-1) was measured in blood samples. A predictive score ranging from 0 to 10 had been previously derived in 649 stable and unstable patients with suspected coronary artery disease (CAD) or MI in the CASABLANCA trial.


  • All patients were followed for one year to assess incident CVE (composite of CV death and incident MI).


  • Application of the prognostic score resulted in an area under receiver operating characteristic curve (AUC) of 0.86 (p<0.001). Application of the optimal cutoff resulted in a high negative predictive value of 99.4% (95%CI 98.7%,100%) and a sensitivity of 86.4% (95%CI 72.0%,100%) for incident CVE. Patients with a prognostic score above the cutoff were more likely to develop a CVE, compared to patients below the cutoff.


  • In this external validation study of patients with suspected MI, the Prevencio HART CVE panel provided high accuracy for predicting incident CVE within one year of follow up.

Scroll Down for ACC Presentation

The ACC 2019 External Validation Presentation for HART CVE

The ACC Publication